Cycle Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cycle Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10965
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cycle Pharmaceuticals Ltd (Cycle) focuses on the development of pharmaceutical products. It acquires, redevelop, and relaunch pharmaceuticals that have been previously marketed. It spans expertise in improving orphan drugs to treat rare diseases. Cycle’s lead drug product includes NITYR (nitisinone) tablets, which is developed for the treatment of hereditary tyrosinemia type-1. The company works in partnership with University of Cambridge, Aarhus University, and University College London to optimise drugs. Cycle is headquartered in Cambridge, the UK.

Cycle Pharmaceuticals Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cycle Pharma Raises Funds through Venture Financing 10
Partnerships 11
Aprecia Pharma and Cycle Pharma Enter into Agreement 11
Licensing Agreements 12
Cycle Pharma Enters into Licensing Agreement with Cambridge Enterprise 12
Caplin Point Labs Enters into Licensing Agreement with Cycle Pharma 13
Equity Offering 14
Intract Pharma Raises Funds in Financing Round 14
Cycle Pharmaceuticals Ltd – Key Competitors 15
Cycle Pharmaceuticals Ltd – Key Employees 16
Cycle Pharmaceuticals Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
11/10/2017: Cycle Pharmaceuticals Launches Free Trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ Dietary Needs 18
08/01/2017: Cycle Pharmaceuticals Receives FDA Approval of Nityr (nitisinone) Tablets for Treatment of HT-1 19
05/31/2018: Cycle Pharmaceuticals receives positive CHMP opinion for Nityr 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cycle Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cycle Pharma Raises Funds through Venture Financing 10
Aprecia Pharma and Cycle Pharma Enter into Agreement 11
Cycle Pharma Enters into Licensing Agreement with Cambridge Enterprise 12
Caplin Point Labs Enters into Licensing Agreement with Cycle Pharma 13
Intract Pharma Raises Funds in Financing Round 14
Cycle Pharmaceuticals Ltd, Key Competitors 15
Cycle Pharmaceuticals Ltd, Key Employees 16

List of Figures
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cycle Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cycle Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CellaVision AB (CEVI):医療機器:M&Aディール及び事業提携情報
    Summary CellaVision AB (CellaVision) is a medical technology company that provides digital solutions for medical microscopy in hematology. The company helps hematology laboratories improve and transform the analysis of blood and other body fluids. It has expertise in digital image analysis, automate …
  • Strongbridge Biopharma plc (SBBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hy …
  • UCO Bank:戦略・SWOT・企業財務分析
    UCO Bank - Strategy, SWOT and Corporate Finance Report Summary UCO Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Westlake Chemical Corporation:企業の戦略・SWOT・財務情報
    Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report Summary Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Gemalto N.V. (GTO):企業の財務・戦略的SWOT分析
    Gemalto N.V. (GTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Misonix Inc (MSON)-医療機器分野:企業M&A・提携分析
    Summary Misonix Inc (Misonix) is a medical technology company that provides ultrasonic surgical devices for neurosurgical, spinal, advanced wound care and general surgery procedures. The company’s major products include BoneScalpel cutting system; SonaStar surgical aspirator; SonicOne wound cleansin …
  • QHR Corporation:医療機器:M&Aディール及び事業提携情報
    Summary QHR Corporation (QHR), a subsidiary of Shoppers Drug Mart Inc. (SDMI), formerly known as QHR Technologies Inc., is a healthcare technology provider. It offers electronic medical records (EMR) for healthcare professionals including family physicians, medical specialists, and surgeons. The com …
  • Kirin Holdings Co Ltd:戦略・SWOT・企業財務分析
    Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Old Mutual Plc:戦略・SWOT・企業財務分析
    Old Mutual Plc - Strategy, SWOT and Corporate Finance Report Summary Old Mutual Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sonoro Energy Ltd (SNV):企業の財務・戦略的SWOT分析
    Summary Sonoro Energy Ltd (Sonoro Energy), formerly Sonic Technology Solutions Inc is an oil and gas company that explores, develops and produces asphalt and bitumen resources. It operates Budong Budong Production Sharing Contract on the coast of western Sulawesi, opposite to Balikpapan that offers …
  • Nakanishi Inc (7716):企業の財務・戦略的SWOT分析
    Nakanishi Inc (7716) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mudman Public Company Limited (MM):企業の財務・戦略的SWOT分析
    Mudman Public Company Limited (MM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Emergent BioSolutions Inc (EBS):企業の財務・戦略的SWOT分析
    Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Deloitte Touche Tohmatsu Limited:企業の戦略・SWOT・財務分析
    Deloitte Touche Tohmatsu Limited - Strategy, SWOT and Corporate Finance Report Summary Deloitte Touche Tohmatsu Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Sarah Cannon Research Institute LLC-製薬・医療分野:企業M&A・提携分析
    Summary Sarah Cannon Research Institute LLC (SCRI) is a research institute that offers integrated cancer services. The institute conducts clinical research programs for advancing cancer therapies. Its services include blood cancer network, cancer care overview, cardiovascular research, contract rese …
  • Mymetics Corp (MYMX):製薬・医療:M&Aディール及び事業提携情報
    Summary Mymetics Corp (Mymetics) is a biotechnology company that develops next-generation prophylactic vaccines for infectious diseases. The company's product pipeline includes vaccine candidates that target HIV-1/AIDS, chikungunya, intranasal influenza, malaria, herpes simplex virus (HSV) and respi …
  • ATUM-製薬・医療分野:企業M&A・提携分析
    Summary ATUM, formerly DNA2.0 Inc is a bioengineering company that provide platforms for protein and vector engineering solutions. The company develops and offers synthetic biology solutions. Its products include expression vectors, electra system, CRISPR/Cas9, proteinpaintbox, cell strains and reag …
  • Forum Energy Metals Corp (FDC):企業の財務・戦略的SWOT分析
    Summary Forum Energy Metals Corp (Forum Energy) formerly Forum Uranium Corp, is a mining and mineral resource company. The company acquires, explores, and develops energy metals, such as uranium and copper in Saskatchewan’s Athabasca Basin. Its projects include Janice Lake Sedimentary Copper Project …
  • Anika Therapeutics Inc (ANIK)-製薬・医療分野:企業M&A・提携分析
    Summary Anika Therapeutics Inc (Anika) is a medical technology company which develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆